SCLC

This page shows the latest SCLC news and features for those working in and with pharma, biotech and healthcare.

More good news, and some bad, for Merck’s Keytruda

treatment for SCLC, which has a five-year survival rate of only 6%. ... The drug is now being studied in combination with chemotherapy in the phase 3 KEYNOTE-604 study in patients with newly-diagnosed, extensive stage SCLC.

Latest news

Nektar confirms BMS deal for NKTR-214 is on track

Robin said that studies are now underway or planned for the CD122-biased agonist in small cell lung cancer (SCLC), breast cancer, colorectal cancer, gastric cancer, triple-negative breast cancer (TNBC)
Astellas, Catalyst approvals set up record year for FDA approvals

Roughly half of LEMS cases are secondary to cancers, and particularly small cell lung cancer (SCLC), and is thought to be caused by an accidental attack of the neuromuscular junction by
AZ’s MYSTIC survival data is in – and it’s a bust

In the meantime, AZ also has trials of Imfinzi with and without tremelimumab running in first- and second-line head and neck cancer, small cell lung cancer (SCLC) and bladder cancer.
Imfinzi aces survival challenge in lung cancer

second-line head and neck cancer, small cell lung cancer (SCLC) and bladder cancer.
FDA green lights BMS’ Opdivo for ‘hard-to-treat’ small cell lung cancer

The treatment, which was approved on Friday, has claimed the title of the first and only immuno-oncology treatment for SCLC patients who have received platinum chemo and at least one ... This ‘hard-to-treat’ disease accounts for up to 15% of all lung

More from news
Approximately 2 fully matching, plus 16 partially matching documents found.

Latest Intelligence

Deal Watch February 2017

triple-negative breast cancer (TNBC), small-cell lung cancer (SCLC), non-small-cell lung cancer (NSCLC) and pancreatic cancer. .
Deal Watch April 2016

Rova-T showed a 44% overall response rate in DLL-expressing small cell lung cancer (SCLC) patients who had failed one or more standard therapies.
Deal Watch November 2015

July finalised a $730m exclusive deal with Boehringer Ingelheim for HM61713, an orally active third generation EGFR agent in small cell lung cancer (SCLC).

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

Featured jobs

Editorial/ Medical Director – Med Ed & Comms – Home-based...: Salary TBC

Editorial / Copy Lead – Healthcare Advertising – Central London...: Salary TBC

Project Manager - Medical Communications – South Wales: Excellent Remuneration Package

Experienced / Senior Account Director - Publications - London: Up to £80, 000 plus great benefits

Account Director, Medical Education: Salary TBC

Director – Healthcare PR: Salary TBC

Senior Account Manager- Pharma and Life Scienes: Competitive salary and benefits

Account Manager, Medical Communications and Marketing: £30, 000 – £40, 000 benefits and bonus

Account Director – London based Medical Communications Agency: Excellent Remuneration Package

Science Writer, Healthcare Advertising Agency: £40, 000 - 45, 000 DOE benefits,

Account Manager / Senior Account Manager - Healthcare Advertisin...: Excellent Remuneration

Hybrid Role - Principal Medical Writer / Account Handler - Publi...: Salary TBC

Senior / Principal Medical Writer - MedComms - Home Based / Vari...: Excellent Remuneration Packages

Senior Medical Writer: Salary TBC

PR Associate Director – Consumer Health & Beauty: Salary TBC

Account Manager, MedicalCommunications/ Healthcare PR: benefits

Senior Medical Writer: Competitive salary and benefits

Home-based Principal Medical Writer – Medical Comms: Salary TBC

Senior Account Director/ Associate Director- Pharma and Life Sci...: Competitive salary and benefits

Editor – Medical Education Agency – Bucks: Salary TBC

Project Manager - Digital Healthcare - London: Excellent Remuneration Package

Freelance Medical Writer - Healthcare Advertising - London: Employment Type:. Type of Job:. Region:. Salary:. 250 to 330 per day

Subscribe to our email news alerts

PMHub

Add my company

COUCH.

WE ARE COUCH – a full service medical communications agency. We are a trusted partner; always striving to help make...

Latest intelligence

From lay summaries to patient engagement programmes: how patient-centricity is finally becoming a reality: How pharma is progressing their commitment in patient engagement...
Cuttsy+Cuttsy awarded CPD Platinum by the IPA: Four years after being awarded Gold for their continuous professional development (CPD) Cuttsy+Cuttsy (C+C) have reached another milestone and been awarded Platinum accreditation....
Breaking Bad: Six behaviours separate the good brand teams from the bad...